Oral Abstract Schedule

Thursday Resident Oral Abstract Schedule

sponsored by


2:15 pm - 2:30 pmGretchen MclindenA novel anti-CD20 monoclonal antibody effective in depleting B-cells in dogs with naive diffuse large B cell lymphoma
2:30 pm - 2:45 pm
Alyssa StrumpfEvaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with high-grade lymphoma
2:45 pm - 3:00 pmMarilia TakadaPhase I clinical trial to evaluate the tolerability of trametinib in dogs with cancer
3:30 pm - 3:45 pm
Abby ReislingVeterinary oncologists' and pet owners' perception of acceptable chemotherapy-related adverse events
3:45 pm - 4:00 pmClarissa FreemyerUse of cystourethroscopy to define the gross tumor volume (GTV) in radiation treatment planning for canine genitourinary carcinomas
4:00 pm - 4:15 pmCaitlin CowanProlonged survival in 57 dogs with thyroid carcinoma treated with radioactive iodine as sole therapy
4:15 pm - 4:30 pmChristian StocksShort-course pre-operative radiation therapy for non-resectable canine mast cell tumors
4:30 pm - 4:45 pmChristine ChangCharacterization of exosomes from histiocytic sarcoma cell lines and their effects on hepatocytes to facilitate formation of the metastatic niche
4:45 pm - 5:00 pmLauren RossF-18-FDG-PET staging of canine multicentric lymphoma


Saturday General Oral Abstract Schedule 

sponsored by


9:00 am - 9:15 amHeather Wilson-RoblesUse of orally administered RTI-76 as a chemotherapy sensitizer for dogs with multicentric lymphoma
9:15 am - 9:30 amKaitlin Curran
Safety and efficacy of rabacfosadine, vincristine, cyclophosphamide, doxorubicin and prednisone (T-CHOP) combination in dogs with treatment naive lymphoma
9:30 am - 9:45 amDouglas ThammRabacfosadine for the treatment of canine plasma cell neoplasia - 18 dogs
9:45 am - 10:00 amKristin M. SnyderEvaluating the induction of antibody-dependent cell-mediated cytotoxicity by canine CD16A and CD64 IgG receptors as a first step towards developing an adoptive cell therapy strategy
2:00 pm - 2:15 pmBrian FlesnerGenomic profiling of canine osteosarcoma by tumor tissue and liquid biopsy testing
2:15 pm - 2:30 pmKate MegquierBlood biopsy as a diagnostic and monitoring tool in canine cancers
2:30 pm - 2:45 pmJong Hyuk KimSingle cell transcriptomic profiling identifies a subpopulation of PIK3CA mutant canine hemangiosarcoma cells with enrichment of pro-inflammatory cytokines
2:45 pm - 3:00 pmHeather GardnerThe genomic landscape of metastatic canine osteosarcoma exhibits conserved structural heterogeneity
3:30 pm - 3:45 pmChad JohannesPost-FDA approval analysis of Stelfonta® (tigilanol tiglate) use by veterinary oncologists for canine mast cell tumors
3:45 pm - 4:00 pm Timothy FanToll-like receptor 9 agonism mediates antimetastatic activities in osteosarcoma and other solid tumor histologies through natural killer cell activation
4:00 pm - 4:15 pmSho YoshimotoSuccessful expression of a PD-1-CD28 switch receptor to overcome PD-L1 mediated inhibition of canine CAR-T cells
4:15 pm - 4:30 pmJennifer LenzDefining the pharmacodynamic profile of STING agonist immunotherapy in dogs with solid tumors
4:30 pm - 4:45 pm
Darrell FisherHigh-dose Precision Radionuclide Therapy (PRnT)
4:45 pm - 5:00 pmMark MamulaPeptide vaccination therapy in canine hemangiosarcoma: Anti-tumor immunity and survival